Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $17.60B · View financials
Snapshot Sep 4, 4:00 PM ET
FY 2026 · Mkt cap
Decision snapshot: MKSI stock price vs ROIV: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ROIV's multiple
Needs ROIV P/E.
Implied fair value · at MKSI's multiple
Needs EPS (TTM) is negative, MKSI P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: MKSI FY 2025 (ended Dec 31, 2025) · ROIV FY 2026 (ended Mar 31, 2026). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 81% equity / 19% debt · EV / Revenue 5.44x · EV / EBITDA 20.37x
Capital structure 98% equity / 2% debt · EV / Revenue 2584.97x
MKSI carries the larger enterprise value at $21.38B against $21.35B; MKSI trades on the lower EV / Revenue multiple (5.44x vs 2584.97x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
MKS INC. · implied price per share
Bear
$21.12
Base
$36.22
Bull
$56.59
ROIVANT SCIENCES LTD. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
1.55x
0.09x
Net debt / EBITDA
Leverage against operating earnings
3.60x
24.52x
Cash and equivalents
Liquid reserves on the balance sheet
$418.00M
$4.29B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Keysight Technologies, Inc.
MKSI vs KEYS
Fortive Corp
MKSI vs FTV
TELEDYNE TECHNOLOGIES INC
MKSI vs TDY
METTLER TOLEDO INTERNATIONAL INC/
MKSI vs MTD
Revolution Medicines, Inc.
MKSI vs RVMD
INCYTE CORP
MKSI vs INCY
Sarepta Therapeutics, Inc.
MKSI vs SRPT
EXELIXIS, INC.
MKSI vs EXEL
VERTEX PHARMACEUTICALS INC / MA
MKSI vs VRTX
$4.20B
$412.94M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
